Recent studies have demonstrated that erythropoietin (EPO) receptors are expressed on tubular epithelial cells and that EPO can protect tubular cells from injury in vitro and in vivo. Separate studies have demonstrated that marrow stromal cells (MSC) exert a renoprotective effect in ischemia/reperfusion and cisplatin tubular injury via the secretion of factors that reduce apoptosis and increase proliferation of tubular epithelial cells. In the current study we demonstrate that MSCs express EPO receptors, and that EPO can protect MSCs from serum-deprivation induced cell death and can stimulate MSC proliferation in vitro. The administration of EPO to mice results in the expansion of CD45-Flk1-CD105+ MSCs in the bone marrow and in the spleen, and mobilizes these cells as well as CD45-Flk1+ endothelial progenitor cells into the peripheral circulation. Consistent with previous reports, the administration of EPO diminished the decline in renal function associated with cisplatin administration. This effect was partially reproduced by the intraperitoneal injection of cultured EPO-mobilized cells in cisplatin treated mice. Thus the in vivo expansion and/or activation of these cells may contribute to the renoprotective effects of EPO to protect tubular cells from toxic injury.